| Product Code: ETC7224346 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 France Neurodegenerative Disease Treatment Market Overview |
3.1 France Country Macro Economic Indicators |
3.2 France Neurodegenerative Disease Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 France Neurodegenerative Disease Treatment Market - Industry Life Cycle |
3.4 France Neurodegenerative Disease Treatment Market - Porter's Five Forces |
3.5 France Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 France Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Drug Type:, 2021 & 2031F |
3.7 France Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Route of Administration:, 2021 & 2031F |
3.8 France Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Distribution Channel:, 2021 & 2031F |
4 France Neurodegenerative Disease Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurodegenerative diseases in France |
4.2.2 Technological advancements in treatment options |
4.2.3 Growing demand for personalized medicine and targeted therapies |
4.2.4 Supportive government initiatives and funding for research and development in neurodegenerative disease treatments |
4.3 Market Restraints |
4.3.1 High cost of neurodegenerative disease treatments |
4.3.2 Regulatory challenges and stringent approval processes |
4.3.3 Limited availability of skilled healthcare professionals specializing in neurodegenerative diseases |
4.3.4 Ethical concerns related to experimental treatments and clinical trials |
5 France Neurodegenerative Disease Treatment Market Trends |
6 France Neurodegenerative Disease Treatment Market, By Types |
6.1 France Neurodegenerative Disease Treatment Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.1.4 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.1.5 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.1.6 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Spinal Muscular Atrophy (SMA), 2021- 2031F |
6.1.7 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Huntingtons Disease, 2021- 2031F |
6.1.8 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.2 France Neurodegenerative Disease Treatment Market, By Drug Type: |
6.2.1 Overview and Analysis |
6.2.2 France Neurodegenerative Disease Treatment Market Revenues & Volume, By N-methyl-D-aspartate Receptor Antagonists, 2021- 2031F |
6.2.3 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Selective Serotonin Reuptake Inhibitors, 2021- 2031F |
6.2.4 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Dopamine Inhibitors, 2021- 2031F |
6.2.5 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 France Neurodegenerative Disease Treatment Market, By Route of Administration: |
6.3.1 Overview and Analysis |
6.3.2 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.4 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 France Neurodegenerative Disease Treatment Market, By Distribution Channel: |
6.4.1 Overview and Analysis |
6.4.2 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 France Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 France Neurodegenerative Disease Treatment Market Import-Export Trade Statistics |
7.1 France Neurodegenerative Disease Treatment Market Export to Major Countries |
7.2 France Neurodegenerative Disease Treatment Market Imports from Major Countries |
8 France Neurodegenerative Disease Treatment Market Key Performance Indicators |
8.1 Patient enrollment in clinical trials for neurodegenerative disease treatments |
8.2 Adoption rate of innovative treatment technologies and therapies |
8.3 Number of research partnerships and collaborations in the field of neurodegenerative diseases |
8.4 Rate of successful drug approvals and market launches for neurodegenerative disease treatments |
8.5 Patient satisfaction and quality of life improvements post-treatment |
9 France Neurodegenerative Disease Treatment Market - Opportunity Assessment |
9.1 France Neurodegenerative Disease Treatment Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 France Neurodegenerative Disease Treatment Market Opportunity Assessment, By Drug Type:, 2021 & 2031F |
9.3 France Neurodegenerative Disease Treatment Market Opportunity Assessment, By Route of Administration:, 2021 & 2031F |
9.4 France Neurodegenerative Disease Treatment Market Opportunity Assessment, By Distribution Channel:, 2021 & 2031F |
10 France Neurodegenerative Disease Treatment Market - Competitive Landscape |
10.1 France Neurodegenerative Disease Treatment Market Revenue Share, By Companies, 2024 |
10.2 France Neurodegenerative Disease Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here